Rein Therapeutics (RNTX) Other Operating Expenses (2020 - 2025)
Rein Therapeutics (RNTX) posted quarterly Other Operating Expenses of $28.7 million for Q4 2025, down 22.43% year-over-year from $37.0 million in Q4 2024, and down 22.43% quarter-over-quarter from $37.0 million in Q4 2024.
Rein Therapeutics (RNTX) Other Operating Expenses (2020 - 2025) Analysis & Trends
Rein Therapeutics (RNTX) has reported Other Operating Expenses for 3 consecutive years, with $28.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Operating Expenses fell 22.43% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $28.7 million (down 22.43% YoY), while the FY2025 annual figure was $28.7 million, down 22.43% from the prior year.
- Other Operating Expenses retreated to $28.7 million in Q4 2025 per RNTX's latest filing, from $37.0 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $37.0 million in Q4 2024 and bottomed at $28.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28.70 Mn |
| Dec 31, 2024 | 37.00 Mn |
| Dec 31, 2020 | 20,000.00 |
| Mar 31, 2020 | 66,000.00 |